Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of irinotecan in patients with advanced metastatic breast cancer who have experienced failure of an anthracycline, a taxane, and capecitabine.

Trial Profile

Phase II trial of irinotecan in patients with advanced metastatic breast cancer who have experienced failure of an anthracycline, a taxane, and capecitabine.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Oct 2008

At a glance

  • Drugs Irinotecan (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Oct 2008 Actual patient number (134) added as reported by ClinicalTrials.gov.
    • 25 Jun 2007 Status changed from in progress to completed
    • 08 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top